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ABSTRACT: Anesthetics are thought to mediate a portion of their activity via binding to
and modulation of potassium channels. In particular, tandem pore potassium channels (K2P)
are transmembrane ion channels whose current is modulated by the presence of general
anesthetics and whose genetic absence has been shown to confer a level of anesthetic
resistance. While the exact molecular structure of all K2P forms remains unknown, signiﬁcant
progress has been made toward understanding their structure and interactions with
anesthetics via the methods of molecular modeling, coupled with the recently released higher
resolution structures of homologous potassium channels to act as templates. Such models
reveal the convergence of amino acid regions that are known to modulate anesthetic activity
onto a common three- dimensional cavity that forms a putative anesthetic binding site. The
model successfully predicts additional important residues that are also involved in the putative
binding site as validated by the results of suggested experimental mutations. Such a model can
now be used to further predict other amino acid residues that may be intimately involved in
the target-based structure−activity relationships that are necessary for anesthetic binding.
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Volatile general anesthetics are thought to act, at least inpart, by binding to and modulating two pore domain
potassium channels (K2P). These K2P potassium channels are
transmembrane ion channels whose current is modulated by
the presence of a wide range of volatile and gaseous general
anesthetics,1−3 and whose genetic knock out, either globally4−6
or locally,7 has been shown to confer a level of anesthetic
resistance. What is not known is where anesthetics bind within
the channels, and how this binding translates into increased
channel opening. For diﬀerent K2P channels, using a
combination of chimeric constructs and site-directed muta-
genesis, a number of amino acids have been identiﬁed as key
anesthetic determinants.8−11 However, whether these determi-
nants function as parts of anesthetic binding sites or are
involved in transduction mechanisms that convert binding into
channel gating is unclear. The covalent modiﬁcation work by
Conway and Cotton suggests that a region around L159 forms
a putative anesthetic binding site.12 Another approach to this
problem is to use the structures of homologous potassium
channels as templates to construct models of an anesthetic-
sensitive channel to investigate the three-dimensional disposi-
tion of these anesthetic determinants. Here we describe how
the construction of such models reveals the convergence of
amino acid regions that are known to aﬀect anesthetic
sensitivity into a common three-dimensional locus that could
serve as an anesthetic binding site. We test our prediction that
particular amino acids form part of an anesthetic binding site
using patch-clamp electrophysiology on wild-type and mutant
K2P channels.
A novel anesthetic-activated potassium current was ﬁrst
characterized in a single molluscan neuron by Franks and
Lieb.13,14 Following this, anesthetic activated mammalian K2P
channels were identiﬁed and knockout mice lacking K2P
channels have demonstrated decreased sensitivities to volatile
anesthetics.2 Within the tandem pore potassium channel family,
TREK-1 is sensitive to the anesthetic gases Xe, N2O, and
cyclopropane, while TASK-3 is insensitive to these gases while
retaining sensitivity to the volatile anesthetics.9 Additional
studies producing single point mutations in TREK-1 conferred
relative resistance to certain volatile anesthetics.8 Through the
generation of TASK-3 knockout mice, Pang et al. showed a
signiﬁcant role for the TASK-3 potassium channel in the theta
oscillations of the cortical EEG that are associated with both
sleep and anesthetized states.6 In particular, TASK-3 knockout
animals show marked alterations in both anesthetic sensitivity
and natural sleep behavior. This is particularly tantalizing, since
certain electrophysiologic aspects of deep (non-REM) sleep
have similarities to the anesthetized state.15,16
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■ RESULTS
Molecular Modeling. We chose to model the TASK
potassium channel from Lymnaea stagnalis (LyTASK), because
this has the greatest sensitivity to volatile anesthetics of any
known K2P channel.8 The BLAST-derived scores suggest a
close homology between LyTASK and two K2P channels
whose structures have been determined to high resolution. The
ﬁrst is the anesthetic-sensitive human TWIK-1 channel,
3UKM17 (51% sequence coverage, 33% maximum amino acid
identity, and BLAST expectation value of 4 × 10−29), and the
second is the human anesthetic-insensitive TRAAK channel,
whose structure has been described with two diﬀerent chain
connectivities 3UM7 and 4I9W18,19 (67% sequence coverage,
31% maximum amino acid identity, and BLAST expectation
value of 3 × 10−31). Subsequent CLUSTALW alignment of the
sequence from LyTASK to the sequence proﬁle (created from
the sequences of the two templates 3UKM and 3UM7) also
demonstrates reasonable sequence similarity (Figure 1).
Models of the anesthetic-sensitive LyTASK based on the
overlapped TWIK-1 and TRAAK template structures show a
dimer with symmetry about a central ion pore. Amino acid
regions notable for modulating anesthetic action on this
channel (L1598 and the amino acid sequence ILRFLT10,11)
converged on a common pocket in three-dimensional space
(Figure 2). This was the case even in a model with the
alternative backbone connectivities based on 4I9W, though the
latter was not used for further analysis. The diﬀerent
connectivity only aﬀected regions that are at the opposite
end of the channel to the putative anesthetic binding site and
therefore is unlikely to impact on our results or conclusions.
Three-dimensional visualization of our model suggested that
L241, L242, and S155 were adjacent to the critical residues
(L159 and the sequence ILRFLT) that have previously been
demonstrated as having large eﬀects on anesthetic modu-
lation.8,10,11 Additionally, the model suggests that the L159
might form part of an interacalated hydrophobic side chain
interaction with L241 and L242 (see Figures 3 and 4) as well as
demonstrating residue proximities that could allow a possible
polar interaction between S155 and R246 (Figure 3). The
disruption of such interactions between alpha helical secondary
structure units could lead to changes in the tertiary structure as
well as the large scale motions of the protein.
Electrophysiology on Wild-Type and Mutant LyTASK
Channels. Cells transfected with wild-type LyTASK cDNA
exhibited robust outwardly rectifying currents that reversed
close to the calculated potassium reversal potential (Figure 5A,
blue line; Figure 5B−F, solid lines). Halothane (3%) resulted in
activation of both wild-type and mutant LyTASK currents
Figure 1. Multiple sequence alignment of the two templates with LyTASK. L159 and the ILRFLT sequences are outlined in boxes. Note the
diﬀerences in the aligned amino acids between LyTASK and 3UKM/TWIK (both anesthetic sensitive) and 3UM7/TRAAK which is anesthetic
insensitive. Amino acid similarity is denoted by shades of blue, with darker indicating greater similarity. Note also the alpha helical structure identiﬁed
by the Kabsh and Sander algorithm for each structure indicated by the orange bars.
Figure 2. Molecular modeling derived from the consensus overlap of
templates reveals a putative general anesthetic binding site. Model of
LyTASK illustrating the positions of two established determinants of
anesthetic sensitivity: L159 and the critical sequence of ILRFLT amino
acids.8,10,11 The putative anesthetic binding pocket is shown by the
pink surface, but its intracellular extent is rather arbitrary due to its
“cave-like” opening in that direction.
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(Figure 5A, red line; Figure 5B−F, dashed lines). The mean
wild-type current, measured at −50 mV, was 448 ± 112 pA
(Figure 6A, Table 1). Mutation of serine 155 to alanine, or
lysine 242 to alanine, had little eﬀect on the control LyTASK
current in the absence of halothane (Figure 6A, Table 1)).
Mutation of serine 155 to tryptophan or lysine 241 to alanine
caused reductions in the LyTASK currents (Figure 6A, Table
1); these reductions were not signiﬁcant compared to wild-type
(Figure 6A, Table 1), but in the case of the S155W mutant
there was a trend toward signiﬁcance (p = 0.06). In both wild-
type and mutant LyTASK channels, halothane (3%) activated
the LyTASK current, but the degree of activation was diﬀerent
(Figure 6B). This was most notable when the degree of
activation was expressed as a percentage of the baseline LyTask
current in the absence of anesthetic. Halothane (3%) activated
the wild-type LyTASK currents by 412 ± 54% (Figure 6C).
The LyTASK L241A and the L242A mutants showed a
signiﬁcantly reduced activation by 3% halothane compared to
the wild-type channel, with 190 ± 11% and 194 ± 14%
activation, respectively (Figure 6C). To test a hypothesized
polar interaction between S155 and R246, we mutated LyTASK
S155 to an alanine. The eﬀect of 3% halothane on this S155A
mutant showed no signiﬁcant diﬀerence compared to wild-type
(393 ± 62% activation). We also mutated S155 to a bulky
aromatic residue, tryptophan, to see if this might mimic the
presence of an anesthetic in our putative binding pocket. The
S155W mutant showed a marked increase in activation by 3%
halothane, with the 1146 ± 20% activation being ∼2.8 times
that of the eﬀect of halothane on the wild-type channel (Figure
6C and Table 1).
■ DISCUSSION
General anesthetics have been employed for over 165 years,
and their use is indispensible in a variety of invasive surgical
procedures and an ever increasing body of screening and
preventive medicine maneuvers (colonoscopy, bronchoscopy,
etc.). The state of general anesthesia is characterized by
profound lack of awareness, plus amnesia, analgesia, and
immobility. Each of these desirable physiological responses is
likely to be a consequence of anesthetic eﬀects on diﬀerent
parts of the central nervous system, and considerable progress
has been made toward identifying these sites.20−22 At the
cellular level, it appears that anesthetics act predominantly at a
relatively small number of molecular targets, in particular,
GABAA receptors, two-pore domain potassium channels, and
NMDA receptors.21 In order to further pinpoint molecular sites
of anesthetic action, a large number of in vitro site-directed
mutagenesis studies have been performed, identifying particular
amino acids and motifs that are required for the eﬀects of both
volatile and intravenous general anesthetics on a wide variety of
ion channels.20−22 Eﬀects have been catalogued across diﬀerent
ion channel proteins without convergence on a single site of
action. Another approach to identify relevant receptors has
involved the genetic modiﬁcation of whole organisms in an
eﬀort to induce resistance to particular anesthetics and to test
the importance of a putative target. To date, two key molecular
targets have emerged from this combination of in vitro and in
vivo approaches: the GABAA receptor and K2P potassium
channels. The N265 M knock-in mutation in the mouse β3
GABAA receptor subunit
23 conferred increased resistance to
both propofol and etomidate for both loss of righting reﬂex (a
rodent surrogate for loss of consciousness in humans) and loss
of response to a painful stimulus. While a great deal of work has
focused on the modeling of anesthetic binding sites within the
GABAA receptor,
24,25 several studies have shown that this class
of proteins is unlikely to mediate all of the eﬀects of anesthetics,
particularly for the volatile agents. It is also likely that
anesthetics act by binding to and modulating K2P potassium
channels.21 The knockout of two diﬀerent tandem pore
potassium channels4−7 conferred enhanced resistance to
volatile general anesthetics.
In this Article, we now show how molecular modeling can be
used to shed light on molecular mechanisms of anesthetic
action as well as more eﬃciently suggest in vitro mutations for
testing of molecular models. In this case, molecular modeling
allows one to leverage the knowledge that is gleaned from the
recently available high-resolution crystallographic coordinates
for K2P potassium channels that are highly homologous to one
Figure 3. Model of LyTASK derived from the consensus overlap of
templates illustrating the position of L159 relative to other adjacent
residues for possible mutational analyses. In particular, note the
positions of L241 and L242. Distances between respective α carbon
atoms are expressed in angstroms. Also notice the distances from R245
to both S155 and Q156 for possible polar interactions.
Figure 4. Expanded view (cylinder rotated 90°) of a possible
anesthetic binding region, as viewed from the intracellular surface
(blue arrow), illustrating the side chain intercalation of LEU 241 and
242 from one α helix with LEU 159 of the adjacent α helix.
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that has been extensively studied by mutagenesis and
electrophysiologic analyses. Mutations at L241 and L242 may
blunt activation by anesthetics possibly through a disruption of
a intercalated hydrophobic side chain interactions (Figure 4).
However, the mutations at S155 seem to only have an eﬀect of
potentiating anesthetic activation when the substituted side
chains are large enough, possibly simulating the presence of
ligand. Initial predictions on the importance of a partial polar
interaction between S155 and R246 seem disproven by the fact
that there is no eﬀect on anesthetic activation when the polar to
nonpolar S155A mutation is introduced. The greater
potentiation by the S155W mutation may indicate that a larger
than normal side chain protruding into an anesthetic binding
site accentuates an eﬀect resulting from anesthetic binding,
especially with the tryptophan side chain being signiﬁcantly
larger than a single halothane molecule. One could postulate
that such an eﬀect may indicate that the anesthetic binding site
in LyTASK could accommodate two halothane molecules, as
has been previously shown on anesthetic binding to cholesterol
oxidase26 and ﬁreﬂy luciferase.27,28
Certain caveats should be noted in regards to interpretations
from our modeling. The templates upon which the homology
modeling are based are of suﬃcient resolution to allow good
side chain visualization. However, there are some residues in
chain B of TRAAK that are not present in the crystal structure.
This causes Modeler to build the same loop in chain B of the
LyTASK model based solely on TWIK, which is more collapsed
in the direction of any binding site, causing slightly diﬀerent
pocket formations in this region versus that composed of
template chains A. Also, the alignment of the positions in the
templates that are homologous to L159 in LyTASK show
reasonable homology (alanines instead of leucine). However,
there is rather poor homology in the regions of the templates
associated with the ILRFLT motif within LyTASK. This leaves
some potential for variability in the alignments. Such
alignments would require experimental validation as has been
presented here.
Furthermore, at this stage, our model does not explain the
diﬀerential anesthetic sensitivities of some K2P channels over
others. Our unpublished preparatory work to the current study
did not demonstrate any notable diﬀerences in pocket sizes
between TRAAK and TWIK in these areas that would account
for diﬀerential anesthetic sensitivities. However, the point of
this work is to demonstrate the convergence of relevant
residues on a common 3D locale that has pocket-like character
allowing quite variable size accessibility from the extracellular
space. Such accessibility is clearly present in both the TRAAK
and TWIK templates. The diﬀerential sensitivity of these
proteins is most likely due to diﬀerent amino acid side chains
being present in the binding pocket, as well as diﬀerent large
Figure 5. Typical electrophysiology current−voltage relations for the WT and mutant LyTASK potassium channels. (A) Schematic diagram showing
current−voltage relation for an untransfected cell (green line), LyTASK transfected cells exhibit a large outwardly rectifying potassium current (blue
line) reversing close to −90 mV (R). In the presence of halothane (red line), the LyTASK current is increased. LyTASK currents are quantiﬁed by
measuring the value of the current at a membrane potential of −50 mV, marked on the diagram is the control LyTASK current “L” and the
halothane-activated LyTASK current, “H”. (B) Wild-type LyTASK. (C) LyTASK S155A mutant. (D) LyTASK L242A mutant. (E) LyTASK S155W
mutant. (F) LyTASK L241A mutant. Solid lines are LyTASK currents in the absence of halothane, and dashed lines are the LyTASK currents in the
presence of 3% halothane. Data were sampled at 20 kHz, and each trace contains 3000 data points. Lines shown are means of 10 individual voltage
ramps for a given cell in each condition.
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scale motions that may aﬀect binding to this site. While the
global homology among templates and LyTASK can be seen in
Figure 1 more clearly, the regional homology is relatively low.
The latter amino acid side chain variability as well as the
amphiphilic nature of the amino acids present both could
contribute to diﬀerential anesthetic sensitivity. Furthermore,
although most work on anesthetic binding to soluble proteins
shows little eﬀect on protein structure when anesthetics bind,
such changes may occur in integral membrane proteins. Either
way, the location of the binding pocket at the surface of K2P
channels, in addition to its amphiphilic character, may lend
itself to a considerable amount of ligand size promiscuity, as
exempliﬁed by the diﬀerential eﬀects of ligands from Xe to
isoﬂurane.
Finally, the localization of residues important for anesthetic
binding may only infer a putative binding site. Another
interpretation could be that such residues merely form a region
which is critical for allosteric modulation of the anesthetic-
mediated eﬀect. Greater evidence for actual anesthetic binding
could come from experiments involving the covalent local-
ization of an anesthetic-like ligand to the putative anesthetic
binding site. Additionally, a concern could be that the open
state probability of residue-241 and -242 mutants may be near
100%. We cannot exclude the possibility that the mutations
aﬀect channel gating, but the fact that we can activate all of the
mutant channels with halothane indicates that the open
probability is less than 100% in all cases. In addition, Conway
and Cotten have shown that LyTASK L159C and
TASK3M159C, both anesthetic resistant, tolerate further
activation by alkylation, implying the channels are not “locked
open” by loss of leucine or methionine in this region and that
acute changes in steric occupancy between residues 241, 242,
and 159 activate the channel.12
■ CONCLUSION
Homology modeling produced a model of the K2P channel
that revealed a putative anesthetic-binding pocket identiﬁed by
the convergence of amino acid residues known to modulate
anesthetic activity. The anesthetic binding pocket model was
validated by the successful prediction of other amino acid
residues also found to alter anesthetic modulation of the
channel due to their spatial proximity to the putative binding
site. Such a model can now be used to further predict other
amino acid residues that may be intimately involved in the
target-based structure−activity relationships that are necessary
for anesthetic binding.
■ METHODS
Molecular Modeling. All protein construction calculations were
performed in the Discovery Studio 3.5 software suite (Accelrys, San
Diego, CA). The amino acid sequence of the K2P channel from the
snail, Lymnaea stagnalis (LyTASK), was obtained from the National
Figure 6. Eﬀect of point mutations in LyTASK currents on (A)
baseline control current at −50 mV (“L” in Figure 5A), (B) halothane
activated current at −50 mV (“H” in Figure 5A), and (C) percentage
activation by halothane. Percentage activation is calculated using (H/L
− 1) × 100%. Values shown are means, and error bars are SEM (n = 7
WT, n = 4 L241A, n = 7 L242A, n = 5 S155A, n = 5 S155W). ***p <
0.001, **p < 0.01, *p < 0.05 compared to WT; one-way ANOVA with
Bonferroni’s post hoc test.
Table 1. Anesthetic Activation of Wild-Type LyTASK and
Mutant Channelsa
channel genotype
percentage activation by
3% halothane
control current
(L) (pA)
wild-type (n = 7) 412 ± 54% 448 ± 112
L241A mutant
(n = 4)
190 ± 11%** 103 ± 4
L242A mutant
(n = 7)
194 ± 14%*** 499 ± 150
S155A mutant
(n = 5)
393 ± 62% 483 ± 99
S155W mutant
(n = 5)
1146 ± 20%*** 23 ± 4
aCurrents were measured at a membrane potential of −50 mV.
Percentage activation was calculated from (H/L − 1) × 100%.
Signiﬁcantly diﬀerent (**p < 0.01; ***p < 0.001) from wild-type
(one-way ANOVA with Bonferroni’s post hoc test).
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Center for Biotechnology (NCBI) database. A BLAST sequence
search29 was performed using this sequence to search for sequences of
high homology from those of known three-dimensional (3D)
structure. The two best-scored homologous human sequences were
downloaded as 3D coordinates for two forms of tandem pore
potassium channels. These were obtained from the Research
Collaboratory for Structural Bioinformatics (RCSB) database30 as
the human two pore domain potassium ion channels known as TWIK-
1 or K2P1 (PDB code: 3UKM)17 at 3.4 Å resolution and TRAAK or
K2P4.1 (PDB code: 3UM7)19 at 3.31 Å resolution. A multiple
structure alignment was performed using the SAlign algorithm31 to
create a sequence proﬁle based upon this structural alignment. A
sequence (from LyTASK) to proﬁle (from the SAlign templates)
alignment was then performed with ClustalW32 so as to align the
sequence of the unknown structure with those of the known
structures. The Modeler module33 was used for assignment of
coordinates for aligned amino acids, the construction of possible
loops, and the initial reﬁnement of amino acid side chains. Side chain
reﬁnement was performed on all residues with only one set of
potassium ions present and both undecanes present after atom typing
with CHARMm34 atom types and CFF charges.35 Molecular
mechanics optimization of the entire structure was performed with
free side chains in vacuo and a 10 kcal mol−1 Å−2 harmonic restraint on
the α carbon protein backbone. Amino acid regions on this channel
that are known to be anesthetic determinants (L1598 and the sequence
ILRFLT11) were mapped onto the resulting structure.
Additional molecular modeling was performed using a modiﬁed
version of a more recently released template of a tandem pore
potassium channel with a diﬀerent amino acid backbone connectivity.
The TRAAK or K2P4.1 channel (PDB code: 4I9W18,19) is a tandem
pore potassium channel that is insensitive to anesthetics, but provides
higher resolution analysis that suggests altered backbone connectivity.
Even though this region of controversial connectivity is quite distant
from the anesthetic binding site in question, another model of
LyTASK was constructed utilizing the amino acid backbone
connectivity corrected to that of 4I9W along with 3UKM as the
primary template. Once again, the LyTASK sequence was aligned to
this, now a mix of templates, via the ClustalW algorithm. The Modeler
module was used for assignment of coordinates for aligned amino
acids, the construction of possible loops, and the initial reﬁnement of
amino acid side chains.
Mutagenesis and Electrophysiology. HEK-293 cells (tsA201)
were plated on glass coverslips and transfected with complementary
DNA for wild-type and mutant L. stagnalis TASK (LyTASK) channels
and green ﬂuorescent protein for identiﬁcation, as described
previously.8 Whole-cell recordings were made using an Axoclamp
200B ampliﬁer (Axon Instruments, Foster City, CA). Pipets (3−5
MΩ) were fabricated from borosilicate glass. The intracellular solution
contained (in mM) 120 KCH3SO4, 4 NaCl, 1 MgCl2, 1 CaCl2, 10
EGTA, 10 HEPES, 3 MgATP, and 0.3 NaGTP, titrated to pH 7.3 with
KOH, and the extracellular solution contained (in mM) 145 NaCl, 2.5
KCl, 1 CaCl2, 2 MgCl2, 10 HEPES, and 10 D-glucose, titrated to pH
7.4 with NaOH. Solutions containing halothane were prepared from
saturated solutions containing extracellular saline, as described
previously.36 Cells were voltage clamped at −80 mV, and voltage
ramps from −120 to 0 mV and from 0 to −80 mV were performed
over 250 ms. Currents were ﬁltered at 100 Hz (−3 dB) using an 8-pole
Bessel ﬁlter (model 900, Frequency Devices Inc., Ottawa, IL), digitized
at 20 kHz (Digidata 1332A, Axon Instruments), and stored on a
computer. Cells transfected with LyTASK channels exhibited out-
wardly rectifying currents, with reversal potentials typically ∼−90 mV,
close to the calculated potassium reversal potential of −98 mV. In
order to quantify baseline LyTASK currents and the eﬀect of
halothane on LyTASK current, we measured the size of the current
at the −50 mV point on the voltage ramp (see Figure 5A, vertical line,
L = baseline current, H = halothane activated current). This holding
potential was chosen to minimize any contribution from endogenous
voltage-gated potassium currents (measurements on untransfected
cells indicated that these endogenous voltage-gated currents were
either minimal or not present). All experiments were carried out at 22
± 2 °C. Percentage activation was calculated from the ratio of the
halothane activated current, H, and the control LyTask current, L,
using the equation: activation = (H/L − 1) × 100%.
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